Sml Biopharm
Biotechnology Research • 
Deogan-ro, 104beon-gil, Korea, Republic of • 1-10 Employees
Company overview
| Headquarters | Deogan-ro, 104beon-gil, 17, R1407, Gwangmyeong-si, Gyeonggi-do 14353, KR |
| Website | |
| NAICS | 541714 |
| Keywords | LNP, Antibody, Cancer Vaccine, Mrna |
| Founded | 2021 |
| Employees | 1-10 |
| Socials |
Key Contact at Sml Biopharm
Yeong-Chan Ahn
BD Director
About Sml Biopharm
At SML Biopharm, we develop advanced therapies using mRNA technology to treat a wide range of diseases. Our key products focus on personalized cancer vaccines for treatments, targeting specific cells in the body to combat diseases like HPV induced cancer. We are also conducting research on mRNA-based therapeutics for various conditions, including infectious and rare diseases, by leveraging in-vivo protein expression.
$
Sml Biopharm revenue & valuation
| Annual revenue | $256,665 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $821,328 |
| Total funding | $3,000,000 |
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Director
Türkiye
United Kingdom
United States
Frequently asked questions
Sml Biopharm is located in Deogan-ro, 104beon-gil, KR.
Sml Biopharm was founded in 2021, making it 5 years old. The company has established itself as a significant player in its industry over this time.
Sml Biopharm has approximately 1-10 employees. The company continues to grow its workforce to support its business operations and expansion.
Sml Biopharm has raised a total of $3,000,000 across 1 funding rounds. This investment has helped the company grow and expand its operations.
4.8
40,000 users
